Preparation and evaluation of poly(<scp>L</scp>‐lactide‐<i>co</i>‐glycolide) (PLGA) microbubbles as a contrast agent for myocardial contrast echocardiography

Cui, Wenjin; Bei, Jianzhong; Wang, Shenguo; Zhi, Guang; Zhao, Yue; Zhou, Xiaoshu; Zhang, Hanwei; Xu, Yu

doi:10.1002/jbm.b.30189

Cited by 82 publications

(73 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14 Many stabilizers such as polyvinyl alcohol, polyvinyl pyrrolidone, and Tween ® 80 are added to prevent PLGA NP aggregation during PLGA NP preparation. 15,16 These stabilizers significantly limit their biomedical application because they do not have functional groups for further modifications. Synthesizing stabilizer-free and biodegradable PLGA NPs was previously successful when significant amounts of drugs could be encapsulated in PLGA NPs , 100 nm in diameter.…”

Section: Introductionmentioning

confidence: 99%

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

Cheng

Shieh³

et al. 2012

IJN

131

View full text Add to dashboard Cite

Background: Effective cancer chemotherapy remains an important issue in cancer treatment, and signal transducer and activator of transcription-3 (Stat3) activation leads to cellular resistance of anticancer agents. Polymers are ideal vectors to carry both chemotherapeutics and small interfering ribonucleic acid (siRNA) to enhance antitumor efficacy. In this paper, poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with paclitaxel and Stat3 siRNA were successfully synthesized, and their applications in cancer cells were investigated. Methods: Firstly, paclitaxel was enclosed by PLGA nanoparticles through solvent evaporation. They were then coated with cationic polyethylenimine polymer (PLGA-PEI-TAX), enabling it to carry Stat3 siRNA on its surface through electrostatic interactions (PLGA-PEI-TAX-S3SI). The size, zeta potential, deliver efficacy, and release profile of the PLGA nanocomplexes were characterized in vitro. The cellular uptake, intracellular nanoparticle trajectory, and subsequent cellular events were evaluated after treatment with various PLGA nanocomplexes in human lung cancer A549 cells and A549-derived paclitaxel-resistant A549/T12 cell lines with α-tubulin mutation. Results: A549 and A549/T12 cells contain constitutively activated Stat3, and silencing Stat3 by siRNA made both cancer cells more sensitive to paclitaxel. Therefore, PLGA-PEI-TAX-S3SI was synthesized to test its therapeutic role in A549 and A549/T12 cells. Transmission electron microscopy showed the size of PLGA-PEI-TAX-S3SI to be around 250 nm. PLGA-PEI nanoparticles were nontoxic. PLGA-PEI-TAX was taken up by A549 and A549/T12 cells more than free paclitaxel, and they induced more condensed microtubule bundles and had higher cytotoxicity in these cancer cells. Moreover, the yellowish fluorescence observed in the cytoplasm of the cancer cells indicates that the PLGA-PEI nanoparticles were still simultaneously delivering Oregon Green paclitaxel and cyanine-5-labeled Stat3 siRNA 3 hours after treatment. Furthermore, after the cancer cells were incubated with the synthesized PLGA nanocomplexes, PLGA-PEI-TAX-S3SI suppressed Stat3 expression and induced more cellular apoptosis in A549 and A549/T12 cells compared with PLGA-PEI-TAX. Conclusion:The PLGA-PEI-TAX-S3SI complex provides a new therapeutic strategy to control cancer cell growth.

show abstract

Section: Introductionmentioning

confidence: 99%

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

Cheng

Shieh³

et al. 2012

IJN

131

View full text Add to dashboard Cite

show abstract

“…Several reports have proposed the use of polymers to increase the stability of UCAs, since polymeric shells would resist dissolution and acoustic pressures better than the monomolecular layers of lipids or proteins usually stabilizing commercial UCAs. [7][8][9][10] Moreover, because of their high difference of density with air and their poor solubility in water, perfluorocarbons have been shown to increase both the stability and the echogenicity of UCAs. [11] Lanza et al [12] as well as Wickline et al [13] have shown that nanoemulsions of liquid perfluorocarbons in water have interesting ultrasound properties similar to gaseous perfluorocarbons, particularly at high frequencies (>15 MHz), and they suggest that such agents would be useful for small animal imaging.…”

mentioning

confidence: 99%

Perfluorooctyl Bromide Polymeric Capsules as Dual Contrast Agents for Ultrasonography and Magnetic Resonance Imaging

Pisani

Tsapis

Galaz

et al. 2008

Adv Funct Materials

120

144

View full text Add to dashboard Cite

Polymeric capsules with a thick shell made of biodegradable and biocompatible polymer and a liquid core of perfluorooctyl bromide (PFOB) were evaluated for stability as well as for ultrasound and magnetic resonance imaging (MRI) contrast enhancement. The method of preparation allows the mean capsule diameter to be regulated between 70 nm and 25 µm and the capsule thickness‐to‐radius ratio from 0.25 to 0.54. Capsule diameter remains stable at 37 °C in phosphate buffer for at least 4 and 6 h for nanocapsules and microcapsules, respectively. The in vitro ultrasound signal‐to‐noise ratio (SNR) was measured from 40 to 60 MHz for 6 µm and 150 nm capsules: the SNR increases with capsule concentration up to 20–25 mg mL−1, and then reaches a plateau that depends on capsule diameter (13.5 ± 1.5 dB for 6 µm and 6 ± 2 dB for the 150 nm capsules). The ultrasound SNR is stable for up to 20 min for microcapsules and for several hours for nanocapsules. For nanocapsules, the thinner the shell, the larger the SNR and the more compressible the capsules. Nanocapsule suspensions imaged in vitro with a commercial ultrasound imaging system (normal and tissue harmonic imaging modes, 7–14 MHz probe) were detected down to concentrations of 12.5 mg mL−1. Injections of nanocapsules (200 µg ml−1) in mice in vivo reveal that the initial bolus passage presents significant ultrasound enhancement of the blood pool during hepatic imaging (7–14 MHz probe, tissue harmonic imaging mode). 19F‐MRI images were obtained in vitro at 9.4T using spin‐echo and gradient echo sequences and allow detecting nanocapsules in suspension (50 mg mL−1). In conclusion, these results show initial feasibility for development of these capsules toward a dual‐modality contrast agent.

show abstract

“…After further stirring with Ultra-turrax T10 (IKA) for 10 min (works for 1 min and stops for 1 min) over ice water, organic solvents were then evaporated by magnetic stirring for about 3 h at room temperature. [15] Characterization Particle size was measured through dynamic light scattering with a Malvern Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, Worcestershire, UK). Transmission electron microscopy (TEM) images were recorded on a JEOL-2100F instrument using an accelerating voltage of 200 kV.…”

Section: Synthesis Of Plga-block-pegmentioning

confidence: 99%

Wang¹,

Li²,

Wang³

et al. 2017

View full text Add to dashboard Cite

These authors contributed equally to this work.Med. Res. 2017, 1, 27-31 Poly(lactic-co-glycolic acid) (PLGA)-block-polyethylene glycol (PEG)/perfluoroctyl bromide (PFOB) emulsion, in which PLGA-block-PEG, as the carrier, is combined with perfluorocty bromide, is developed to improve arterial hypoxemia and ameliorate the lung ventilation through pulmonary drug delivery. The cell viability increased obviously, which shows that the emulsion has certain positive effects on the cell proliferation. Moreover, the emulsion can help cells quickly recover from the anoxic symptoms as indicated by cell hypoxia-reoxygenation experiment. When cells were incubated with the emulsion under hypoxia, an obvious increase of cell growth was observed, which indicated that the emulsion was capable of providing sufficient oxygen for cells. Then we established two different models of rabbits to investigate whether the PLGA-b-PEG/PFOB emulsion could improve lung ventilation of animals. The impressive result confirmed that the lung ventilation was ameliorated significantly after treatment of emulsion for a period of time. The histological assays further verified the emulsion had good biocompatibility. Furthermore, the concentration of HIF-1 alpha in tissues were evaluated by immunohistochemistry and western respectively to confirm the fact that the emulsion could significantly promote the expression of HIF-1 alpha in lung tissue cells which may have important contributions to tissue survival. In summary, the emulsion was confirmed to supply oxygen for cells and organisms to improve arterial hypoxemia, which reflects the tremendous potential application value in the field of alleviating hypoxemia in future.

show abstract

Preparation and evaluation of poly(L‐lactide‐co‐glycolide) (PLGA) microbubbles as a contrast agent for myocardial contrast echocardiography

Cited by 82 publications

References 31 publications

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

Perfluorooctyl Bromide Polymeric Capsules as Dual Contrast Agents for Ultrasonography and Magnetic Resonance Imaging

Contact Info

Product

Resources

About

Preparation and evaluation of poly(L‐lactide‐co‐glycolide) (PLGA) microbubbles as a contrast agent for myocardial contrast echocardiography

Cited by 82 publications

References 31 publications

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells

Perfluorooctyl Bromide Polymeric Capsules as Dual Contrast Agents for Ultrasonography and Magnetic Resonance Imaging

&nbsp;

Contact Info

Product

Resources

About